The PLASMACARD study was funded by a grant from the French Ministry of Health (“PHRC 2002”), and AD received a study grant from the Fondation pour la Recherche Médicale (FRM). This study was sponsored by the Bordeaux University Hospital (CHU Bordeaux).
Fresh-frozen plasma transfusion did not reduce 30-day mortality in patients undergoing cardiopulmonary bypass cardiac surgery with excessive bleeding: the PLASMACARD multicenter cohort study
Article first published online: 30 SEP 2013
© 2013 American Association of Blood Banks
Volume 54, Issue 4, pages 1114–1124, April 2014
How to Cite
Doussau, A., Perez, P., Puntous, M., Calderon, J., Jeanne, M., Germain, C., Rozec, B., Rondeau, V., Chêne, G., Ouattara, A., Janvier, G. and PLASMACARD Study Group (2014), Fresh-frozen plasma transfusion did not reduce 30-day mortality in patients undergoing cardiopulmonary bypass cardiac surgery with excessive bleeding: the PLASMACARD multicenter cohort study. Transfusion, 54: 1114–1124. doi: 10.1111/trf.12422
- Issue published online: 11 APR 2014
- Article first published online: 30 SEP 2013
- Manuscript Accepted: 4 JUL 2013
- Manuscript Revised: 3 JUL 2013
- Manuscript Received: 2 JAN 2013
- French Ministry of Health (“PHRC 2002”)
- Fondation pour la Recherche Médicale (FRM)
- Bordeaux University Hospital (CHU Bordeaux)
During on-pump cardiac surgery, hemorrhagic complications occur frequently. Fresh-frozen plasma (FFP) is widely transfused to provide coagulation factors. Yet, no randomized clinical trial has demonstrated its benefits on mortality. We assessed the relationship between therapeutic transfusion of FFP and 30-day mortality in cardiac surgery patients suffering from excessive bleeding in a prospective cohort study.
Study Design and Methods
Adult patients who underwent on-pump cardiac surgery and experienced excessive bleeding during the 48-hour perioperative period were recruited from 15 French centers between February 2004 and January 2006. Patients who received a preventive FFP transfusion were excluded. The association between FFP transfusion and all cause 30-day mortality was estimated using a Cox proportional hazards model, adjusted for confounding. A propensity score (PS) sensitivity analysis was also performed.
Among 967 patients included in this study, 58.1% received FFP. The median dose was 11.3 mL/kg (interquartile range, 7.6-19.5). The cumulative 30-day mortality rate was 11.3% (95% confidence interval [CI], 9.5-13.5). FFP transfusion was associated with a higher 30-day mortality (hazard ratio [HR], 3.2; 95% CI, 1.7-6.1) in univariate analysis; however, after adjusting for prognostic factors, there was no longer any association (HR, 1.5; 95% CI, 0.8-3.0, p = 0.20). The results of the PS analysis were consistent with the adjusted analysis.
Among on-pump cardiac surgery patients experiencing excessive perioperative bleeding, there is no evidence of a beneficial impact of FFP transfusion on mortality.